Obesity, body composition, and prostate cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Fowke, Jay H ^a   Motley, Saundra S ^a   Concepcion, Raoul S ^b   Penson, David F ^a,c   Barocas, Daniel A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Urology Associates   (United States)

^c GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BIOELECTRIC IMPEDANCE ANALYSIS; BODY COMPOSITION; BODY FAT; BODY FAT MASS; BODY MASS; CANCER CLASSIFICATION; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FAT FREE MASS; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; PROSTATE BIOPSY; PROSTATE CANCER; WAIST CIRCUMFERENCE; AGED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PROSTATE TUMOR; REGRESSION ANALYSIS;

DIAGNOSTIC AGENT;

AGED; BODY COMPOSITION; BODY MASS INDEX; ELECTRIC IMPEDANCE; HUMANS; MALE; MIDDLE AGED; OBESITY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; WAIST CIRCUMFERENCE;

EID: 84855894719     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-23     Document Type: Article

References (32)

1. American Cancer Society Cancer Facts & Figures 2011 2011, American Cancer Society.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328. 10.1056/NEJMoa0810084, 19297566.
3. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The Risks and Benefits of 5alpha-Reductase Inhibitors for Prostate-Cancer Prevention. N Engl J Med 2011, 365(2):97-99. 10.1056/NEJMp1106783, 21675880.
4. Kristal AR, Gong Z. Obesity and prostate cancer mortality. Future Oncol 2007, 3:557-567. 10.2217/14796694.3.5.557, 17927521.
5. Littman AJ, White E, Kristal AR. Anthropometrics and prostate cancer risk. Am J Epidemiol 2007, 165:1271-1279. 10.1093/aje/kwm013, 17395597.
6. Fowke JH, Matthews CM, Buchowski MS, Signorello LB, Chang SS, Cookson MS, et al. Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. Prostate Cancer Prostatic Dis 2008, 11:264-269. 10.1038/sj.pcan.4501022, 17938644.
7. DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 2010, 3:1451-1461.
8. Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond) 2010, 34:791-799.
9. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond) 2008, 32:959-966.
10. Ezzati M, Martin H, Skjold S, Vander HS, Murray CJ. Trends in national and state-level obesity in the USA after correction for self-report bias: analysis of health surveys. J R Soc Med 2006, 99:250-257. 10.1258/jrsm.99.5.250, 1457748, 16672759.
11. MacInnis R, English D. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006, 17:989-1003. 10.1007/s10552-006-0049-z, 16933050.
12. Wallstrom P, Bjartell A, Gullberg B, Olsson H, Wirfalt E. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. Br J Cancer 2009, 100:1799-1805. 10.1038/sj.bjc.6605077, 2695694, 19436298.
13. Wannamethee SG, Shaper AG, Morris RW, Whincup PH. Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am J Clin Nutr 2005, 81:1313-1321.
14. Kyle UG, Genton L, Pichard C. Body composition: what's new?. Curr Opin Clin Nutr Metab Care 2002, 5:427-433. 10.1097/00075197-200207000-00012, 12107379.
15. Niemann B, Chen Y, Teschner M, Li L, Silber RE, Rohrbach S. Obesity induces signs of premature cardiac aging in younger patients: the role of mitochondria. J Am Coll Cardiol 2011, 57:577-585. 10.1016/j.jacc.2010.09.040, 21272749.
16. Sun G, French CR, Martin GR, Younghusband B, Green RC, Xie YG, et al. Comparison of multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for assessment of percentage body fat in a large, healthy population. Am J Clin Nutr 2005, 81:74-78.
17. Boneva-Asiova Z, Boyanov MA. Body composition analysis by leg-to-leg bioelectrical impedance and dual-energy XΓÇôray absorptiometry in non-obese and obese individuals. Diabetes Obes Metab 2008, 10:1012-1018. 10.1111/j.1463-1326.2008.00851.x, 18435776.
18. Dey DK, Bosaeus I. Comparison of bioelectrical impedance prediction equations for fat-free mass in a population-based sample of 75 y olds: the NORA study. Nutrition 2003, 19:858-864. 10.1016/S0899-9007(03)00172-2, 14559321.
19. Oreopoulos A, Kalantar-Zadeh K, McAlister FA, Ezekowitz JA, Fonarow GC, Johnson JA, et al. Comparison of direct body composition assessment methods in patients with chronic heart failure. J Card Fail 2010, 16:867-872. 10.1016/j.cardfail.2010.06.416, 21055650.
20. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003, 5:87-90. 10.1038/ncb0203-87, 12563267.
21. Perrini S, Laviola L, Carreira MC, Cignarelli A, Natalicchio A, Giorgino F. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol 2010, 205:201-210. 10.1677/JOE-09-0431, 20197302.
22. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002, 94:1099-1106. 10.1093/jnci/94.14.1099, 12122101.
23. Kaaks R, Lukanova A, Rinaldi S, Biessy C, Soderberg S, Olsson T, et al. Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls. Eur J Cancer Prev 2003, 12:309-315. 10.1097/00008469-200308000-00011, 12883384.
24. Cheng I, Stram DO, Penney KL, Pike M, Le Marchand L, Kolonel LN, et al. Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. JNCI Cancer Spect 2006, 98:123-134.
25. Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, et al. Insulin-like growth factor-binding protein-3 gene-202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 2003, 63:4407-4411.
26. Zadra G, Priolo C, Patnaik A, Loda M. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res 2010, 16:3322-3328. 10.1158/1078-0432.CCR-09-1955, 3176306, 20423984.
27. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001, 3:1014-1019. 10.1038/ncb1101-1014, 11715023.
28. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:213-222. 10.1056/NEJMp038121, 12867605.
29. Miner MM. Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ?. Curr Urol Rep 2009, 10:254-260. 10.1007/s11934-009-0042-7, 19570485.
30. Yialamas MA, Hayes FJ. Androgens and the ageing male and female. Best Pract Res Clin Endocrinol Metab 2003, 17:223-236. 10.1016/S1521-690X(03)00018-6, 12787549.
31. Sattler FR, Castaneda-Sceppa C, Binder EF, Schroeder ET, Wang Y, Bhasin S, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab 2009, 94:1991-2001. 10.1210/jc.2008-2338, 2690426, 19293261.
32. Fowke JH, Motley SS, Cookson MS, Concepcion R, Chang SS, Wills ML, et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 2006, 10:137-142.